<?xml version="1.0" encoding="UTF-8"?>
<p id="p0230">Favipiravir treatment increases the frequency of transition (
 <xref rid="bb0120" ref-type="bibr">Delang et al., 2014</xref>; 
 <xref rid="bb0185" ref-type="bibr">Goldhill et al., 2019</xref>; 
 <xref rid="bb0600" ref-type="bibr">Vanderlinden et al., 2016</xref>) and transversion (
 <xref rid="bb0040" ref-type="bibr">Baranovich et al., 2013</xref>) in viral genomes, and these mutations are hypothesized to be caused by favipiravir, resulting in lethal mutagenesis (
 <xref rid="bb0040" ref-type="bibr">Baranovich et al., 2013</xref>; 
 <xref rid="bb0120" ref-type="bibr">Delang et al., 2014</xref>; 
 <xref rid="bb0185" ref-type="bibr">Goldhill et al., 2019</xref>; 
 <xref rid="bb0600" ref-type="bibr">Vanderlinden et al., 2016</xref>). We observed a transition of influenza virus and poliovirus in cultures treated with favipiravir but did not assess the frequency because we were unable to compare the transition rate with the proper antiviral agents with similar mechanisms as a control (
 <xref rid="bb0095" ref-type="bibr">Daikoku et al., 2017</xref>; 
 <xref rid="bb0105" ref-type="bibr">Daikoku, Yoshida, Okuda, &amp; Shiraki, 2014</xref>).
</p>
